Rush Hymenoptera venom immunotherapy:: A safe and practical protocol for high-risk patients

被引:93
|
作者
Sturm, G [1 ]
Kränke, B [1 ]
Rudolph, C [1 ]
Aberer, W [1 ]
机构
[1] Graz Univ, Dept Environm Dermatol & Allergy, A-8036 Graz, Austria
关键词
honeybee venom; Hymenoptera venom allergy; rush immunotherapy; side effects; yellow jacket venom;
D O I
10.1067/mai.2002.129124
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Hymenoptera venom immunotherapy in allergic patients is a well-established treatment modality for the prevention of systemic anaphylactic reactions caused by insect stings. A variety of therapy regimens exists, from conventional to rush and ultrarush modalities that operate on continuous or intermittent schedules. Objective: The aim of this study was to report the 8-year experience with our rush venom immunotherapy regimen in predominantly high-risk patients and to compare data on safety and convenience with the results of 26 studies published from 1978 to 2001. Methods: One hundred one patients allergic to bee, yellow jacket, or hornet venom were treated with rush Hymenoptera venom immunotherapy. Diagnosis and selection of patients for venom immunotherapy were carried out according to the recommendations of the European Academy of Allergology and Clinical Immunology. We used a 4-day regimen, and the incidence and nature of systemic reactions (SRs) were documented. Fifty-two patients were treated with honeybee venom, and 49 were treated with yellow jacket venom. Results: One hundred (99%) patients reached the maintenance dose. We observed 8 injection-related SRs (0.47% of all injections given) in 7 (6.9%) patients. The number of SRs was higher in patients treated with bee venom extract (12%) compared with in patients receiving yellow jacket venom extract (2%). There was no significant difference in the risk of SRs between female and male patients. The incidence of SRs was considerably lower than the average of 17.8% reported in the literature. Conclusion: With a rush immunotherapy regimen over a time period of 8 years in predominantly high-risk patients, the incidence of SRs was low, despite the high number of patients with bee venom allergy, who are more likely to have side effects. Epinephrine as rescue medication was never necessary, and the regimen proved to be safe and convenient for both the patients and the medical staff.
引用
收藏
页码:928 / 933
页数:6
相关论文
共 50 条
  • [31] RAPID VENOM IMMUNOTHERAPY IS SAFE FOR ROUTINE USE IN THE TREATMENT OF PATIENTS WITH HYMENOPTERA-ANAPHYLAXIS
    BERNSTEIN, JA
    KAGEN, SL
    BERNSTEIN, DI
    BERNSTEIN, IL
    ANNALS OF ALLERGY, 1994, 73 (05): : 423 - 428
  • [32] SUCCESSFUL USE OF OMALIZUMAB WITH VENOM IMMUNOTHERAPY IN A HIGH-RISK CHILD
    Tran, P.
    Lee, J.
    Cianferoni, A.
    Fontana-Penn, M.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S67 - S67
  • [33] A short, safe rush-induction protocol for aeroallergen immunotherapy
    Hajirawala, Monica
    Hardeman, Amber
    Huntwork, Margaret P.
    Carlson, John C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : 661 - 662
  • [34] Release of granzyme B (GzmB) from peripheral blood leukocytes in patients with hymenoptera venom allergy - effect of rush venom immunotherapy
    Klos, Zuzanna
    Kujawiak, Magdalena
    Chalubinski, Maciej
    Kosinski, Slawomir
    Cieslak, Malgorzata
    Smorawska, Ewa
    Grzelak, Aneta
    Kowalski, Marek L.
    Grzegorczyk, Janina
    ALERGIA ASTMA IMMUNOLOGIA, 2009, 14 (01): : 55 - 62
  • [35] A 2-h ultra rush venom immunotherapy protocol in children
    Mitsias, D.
    Piskou, K.
    Douladiris, N.
    Papadopoulos, N.
    Manoussakis, E.
    ALLERGY, 2010, 65 : 264 - 264
  • [36] Sublingual immunotherapy with venom is not recommended for patients with Hymenoptera venom allergy
    Rueff, Franziska
    Bilo, M. Beatrice
    Jutel, Marek
    Mosbech, Holger
    Mueller, Ulrich
    Przybilla, Bernhard
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2009, 123 (01) : 272 - 273
  • [37] Ultra-rush protocols for hymenoptera venom immunotherapy in mastocytosis: What about tolerance?
    Gruzelle, V
    Ramassamy, M.
    Livideanu, Bulai C.
    Didier, A.
    Maihol, C.
    Guilleminault, L.
    ALLERGY, 2018, 73 : 639 - 639
  • [38] LOSS OF TOTAL HISTAMINE ACTIVITY AS AN EXPLANATION FOR SUCCESSFUL RUSH-IMMUNOTHERAPY WITH HYMENOPTERA VENOM
    STEPHAN, V
    URBANEK, R
    KOWNATZKI, E
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1987, 79 (01) : 232 - 232
  • [39] Depot extracts for rush venom immunotherapy A new therapeutic opportunity for Hymenoptera sting allergy
    Pucci, Stefano
    Ciccarelli, Fedra
    De Pasquale, Tiziana
    Illuminati, Ilenia
    D'Alo, Simona
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (03) : 376 - 377
  • [40] HYMENOPTERA HYPERSENSITIVITY IN A PATIENT FOUND TO HAVE SYSTEMIC MASTOCYTOSIS, TREATED WITH RUSH VENOM IMMUNOTHERAPY
    Li, M.
    Katial, R.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S27 - S27